NovoCure (NVCR) Stock Price, News & Analysis

Company Overview

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire. The company entered the public markets with a Nasdaq IPO in December 2015, expanding its ability to fund clinical research and commercial deployment of its TTFields technology.

Its flagship device, Optune, received regulatory approvals for recurrent and newly diagnosed glioblastoma multiforme in the U.S., Europe and other jurisdictions. Optune uses a portable electric field generator and transducer arrays worn on the scalp, representing a paradigm shift in the management of brain tumors. In addition to GBM, NovoCure is actively conducting clinical trials in pancreatic, ovarian, lung and liver cancers, as well as exploring applications in mesothelioma through its Optune Lua device.

NovoCure markets its products across North America, Europe and the Asia-Pacific region, emphasizing patient access programs and physician engagement to drive adoption. The leadership team is spearheaded by founder and Chief Technology Officer Yoram Palti, whose foundational research underpins the TTFields platform, supported by a seasoned executive cadre overseeing global operations, regulatory affairs and clinical development.

Key Stats

• Today's Range: $11.71 to $12.39
• 50-Day Range: $10.90 to $18.46
• 52-Week Range: $10.87 to $34.13
• Volume: 1.09 million shs
• Average Volume: 1.45 million shs
• Market Capitalization: $1.35 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.79
• Consensus Rating: Moderate Buy

NovoCure Stock Analysis - MarketRank™

NovoCure scored higher than 80% of companies evaluated by MarketBeat, and ranked 203rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

NovoCure has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for NovoCure are expected to decrease in the coming year, from ($1.30) to ($1.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NovoCure is -7.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NovoCure is -7.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NovoCure has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.57% of the float of NovoCure has been sold short.

Short Interest Ratio / Days to Cover

NovoCure has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NovoCure has recently increased by 5.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NovoCure does not currently pay a dividend.

Dividend Growth

NovoCure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.15

Percentage of Shares Shorted

5.57% of the float of NovoCure has been sold short.

Short Interest Ratio / Days to Cover

NovoCure has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NovoCure has recently increased by 5.56%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.71

News Sentiment

NovoCure has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for NovoCure this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for NVCR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

2 people have added NovoCure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, NovoCure insiders have bought more of their company's stock than they have sold. Specifically, they have bought $231,800.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 5.52% of the stock of NovoCure is held by insiders.

Percentage Held by Institutions

84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NVCR Stock Analysis - Frequently Asked Questions

How have NVCR shares performed this year?

NovoCure's stock was trading at $29.80 at the beginning of 2025. Since then, NVCR stock has decreased by 59.5% and is now trading at $12.08.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) posted its quarterly earnings results on Thursday, July, 24th. The medical equipment provider reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. The business's revenue was up 5.6% compared to the same quarter last year.
Read the conference call transcript.

Who are NovoCure's major shareholders?

NovoCure's top institutional shareholders include Soleus Capital Management L.P. (6.18%), Geode Capital Management LLC (2.19%), Balyasny Asset Management L.P. (2.03%) and Marshall Wace LLP (1.27%). Insiders that own company stock include Wilhelmus Cm Groenhuysen, Ashley Cordova, W Anthony Vernon, Frank X Leonard, Christoph Brackmann, Pritesh Shah, Michal Nath Puri, Uri Weinberg, Asaf Danziger and Mukund Paravasthu.
View institutional ownership trends.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NovoCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovoCure investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Chembio Diagnostics (CEMI), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC).

Company Calendar

• Last Earnings: 7/24/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NVCR
• CIK: 1645113
• Web: www.novocure.com
• Phone: 441534756700
• Fax: N/A
• Employees: 1,488
• Year Founded: 2000

Price Target and Rating

• Average Price Target for NovoCure: $28.79
• High Price Target: $38.00
• Low Price Target: $14.50
• Potential Upside/Downside: +144.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$168.63 million
• Net Margins: -27.13%
• Pretax Margin: -22.54%
• Return on Equity: -47.74%
• Return on Assets: -13.79%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 1.45
• Quick Ratio: 1.39

Sales & Book Value

• Annual Sales: $605.22 million
• Price / Sales: 2.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.13 per share
• Price / Book: 3.77

Miscellaneous

• Outstanding Shares: 111,800,000
• Free Float: 105,628,000
• Market Cap: $1.32 billion
• Optionable: Optionable
• Beta: 0.58